Logo Logo

Category Archives: "News"

  1. Home
  2. INforMS
  3. Page 12
Apr 30, 2019
FDA approves MAVENCLAD® (Cladribine) tablets
INforMS
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's [...]
Elizabeth Porco
Read More
...37
0
Apr 19, 2019
OHSU doctors part of ‘breakthrough’ research on treating multiple sclerosis
INforMS, Partners
PORTLAND, Ore. (KATU) – They're calling it a potential game-changer. Doctors at Oregon Health and Science University are part of a new [...]
Elizabeth Porco
Read More
...40
0
Apr 15, 2019
Anne Cross, neurologist with pioneering work into B-cells/multiple sclerosis, awarded John Dystel Prize
INforMS, Partners
This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS chair in the [...]
Elizabeth Porco
Read More
...42
0
Mar 29, 2019
Novartis gets FDA approval for Mayzent (Siponimod), the first oral drug to treat SPMS
INforMS, Partners
EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA) has approved [...]
Elizabeth Porco
Read More
...42
0
Mar 27, 2019
Novartis receives FDA approval for MAYZENT (Siponimod)
INforMS, Partners
- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis [...]
Elizabeth Porco
Read More
...38
0
Mar 26, 2019
Dose-finding study for SAR442168 in relapsing multiple sclerosis
INforMS
Brief Summary: Primary Objective: To determine the efficacy of SAR442168 in reducing the number of new brain lesions reported in [...]
Elizabeth Porco
Read More
...38
0
Mar 14, 2019
BrainStorm announces first patient in phase 2 clinical trial progressive multiple sclerosis
INforMS
NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE)—BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing [...]
Elizabeth Porco
Read More
...42
0
Feb 19, 2019
Depression, psychological distress symptoms affect multiple sclerosis patients’ quality of life
INforMS, MS Community
Depression and psychological distress symptoms can have a huge effect on the way multiple sclerosis (MS) patients view their well-being, [...]
Elizabeth Porco
Read More
...42
0
Feb 06, 2019
In memoriam of Dr. Lael Stone
CMSC PR
Lael Stone, age 59, Died peacefully on February 4, 2019, at the Maltz Hospice House, Beachwood, Ohio, surrounded by her family. She was [...]
Elizabeth Porco
Read More
...42
0
Dec 18, 2018
FDA accepts BrainStorm’s NurOwn® IND application for progressive multiple sclerosis
INforMS
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative [...]
Elizabeth Porco
Read More
...40
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM